LY2090314
CAY-22211-25 25 mg
Data Sheet: 
SDS:
SDS:
CAS
603288-22-8
Formulation
A crystalline solid
Purity
≥98%
MW
512,5
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A potent and selective inhibitor of GSK3 (IC50s = 1.5 and 0.9 for human recombinant GSK3α and GSK2β, respectively); has >10-fold selectivity for GSK3 against a panel of 40 kinases at a concentration of 20 μM; induces time-dependent stabilization of β-catenin total protein and activates Wnt signaling in vitro; has potent antiproliferative activity in BRAF wild-type/NRAS mutant and BRAF mutant melanoma cell lines (IC50s = 6.0-11.8 nM) but has limited to no activity in non-melanoma cell lines (IC50s = 430 to >20,000 nM); knockdown of β-catenin in A375 and M14 melanoma cells induces LY2090314 resistance in vitro; reduces tumor volume in a murine A375 xenograft model as a single agent and synergizes with decabarzine for a greater antitumor effect
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
